Description
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening
illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for
HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio
of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available
in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection
in certain high-risk adults.